Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -96.20% | -40.40% | -49.43% | 15.97% | 7.87% |
| Total Depreciation and Amortization | -15.79% | 1.79% | -12.34% | -5.17% | -79.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 339.97% | 408.14% | 1,630.76% | 550.99% | 243.55% |
| Change in Net Operating Assets | -57.68% | 112.09% | -40.62% | -199.36% | -2,957.14% |
| Cash from Operations | -54.09% | 0.95% | -36.31% | 20.65% | 14.57% |
| Capital Expenditure | -500.00% | 92.56% | 78.30% | -- | 97.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -500.00% | 92.56% | 78.30% | -- | 97.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 29.47% | -26.25% | -56.92% | -- |
| Issuance of Common Stock | 81.67% | 16.64% | 1,444.60% | 191.43% | 159.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.53% | -64.08% | 48.95% | -550.38% | -102.82% |
| Cash from Financing | 82.02% | 5.52% | 2,469.40% | 169.06% | 277.22% |
| Foreign Exchange rate Adjustments | -120.51% | 148.03% | 213.32% | -332.76% | -77.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.05% | 30.29% | 57.12% | 85.91% | 88.98% |